Pharmacovigilance Market

Pharmacovigilance sales will expand through 2036, with clinical trial pharmacovigilance at 28.7% within the type of pharmacovigilance segment and clinical phase at 35.0% of the phases category in 2026. The market was valued at USD 9.0 billion in 2025 and is forecast to record an 8.8% CAGR between 2026 and 2036.